Corrigendum to "Cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban national immunization programme" [Int. J. Infect. Dis. 97 (2020) 182-189].

The authors regret that the Methods section has error in the formula. Corrections follow. In the Modelling approach section… For a given week (w) of age, the number of disease events D<inf>w</inf> was calculated as: [Figure presented] where: P × S × A<inf>w</inf> is the number of disease events in week w of age; V<inf>w</inf> is the effect of vaccination in week w of age; P is the number of person-years lived between birth and age 5.0 years in the birth cohort evaluated; S is the streptococcus pneumoniae (pneumococcal) disease event rate per 100,000 per year among children younger than 5 years before the introduction of vaccination; and A<inf>w</inf> is the proportion of pneumococcal disease events in children younger than 5 years in week w of age. In the Pneumococcal disease burden inputs section… For each birth cohort, estimates of person-years lived between birth and age 5.0 years (P) were based on United Nations demographic projections (https://population.un.org/wpp/). We estimated disease event rates (S) separately for pneumococcal acute otitis media (AOM), non-severe pneumococcal pneumonia, severe pneumococcal pneumonia, pneumococcal meningitis and other non-pneumonia/non-meningitis pneumococcal disease (NPNM) (Table 1). The authors would like to apologise for any inconvenience caused.